Philip R. Hamann

2.9k citations

28 papers · 2.0k indexed · h-index 20

Oncology top 5%
Radiology, Nuclear Medicine and Imaging top 1%
Molecular Biology
Organic Chemistry top 5%
Pathology and Forensic Medicine top 5%

Co-authors: Lois M. Hinman Janis Upeslacis Arthur Kunz Carl F. Beyer Irwin Hollander Nitin K. Damle John F. DiJoseph Erwin R. Boghaert
Topics: Monoclonal and Polyclonal Antibodies Research (12 papers)Chemical Synthesis and Analysis (6 papers)CAR-T cell therapy research (5 papers)
Cited by: Radiology, Nuclear Medicine and Imaging Oncology Hematology
Journals: Nature Journal of the American Chemical Society Blood
Partner nations: United States United Kingdom Canada

In The Last Decade

Philip R. Hamann

28 papers receiving 1.9k citations

Peers

Countries citing papers authored by Philip R. Hamann

Since Specialization

Citations

This map shows the geographic impact of Philip R. Hamann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip R. Hamann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip R. Hamann more than expected).

Fields of papers citing papers by Philip R. Hamann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip R. Hamann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip R. Hamann. The network helps show where Philip R. Hamann may publish in the future.

Co-authorship network of co-authors of Philip R. Hamann

This figure shows the co-authorship network connecting the top 25 collaborators of Philip R. Hamann. A scholar is included among the top collaborators of Philip R. Hamann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip R. Hamann. Philip R. Hamann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selection of Reaction Additives Used in the Preparation of Monomeric Antibody−Calicheamicin Conjugates 2007 ·Bioconjugate Chemistry ·Irwin Hollander,Arthur Kunz,Philip R. Hamann	56
2	Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples 2007 ·Cancer Chemotherapy and Pharmacology ·Erwin R. Boghaert,Kiran Khandke,Latha Sridharan,Maureen Dougher,John F. DiJoseph,Arthur Kunz,Philip R. Hamann,Justin Moran,Indrasish Ray Chaudhuri,Nitin K. Damle	49
3	Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma 2006 ·Clinical Cancer Research ·John F. DiJoseph,Maureen Dougher,(unknown),Douglas Armellino,Erwin R. Boghaert,Philip R. Hamann,Justin Moran,Nitin K. Damle	103
4	CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab 2006 ·Cancer Immunology Immunotherapy ·John F. DiJoseph,Maureen Dougher,Douglas Armellino,(unknown),Arthur Kunz,Erwin R. Boghaert,Philip R. Hamann,Nitin K. Damle	42
5	Monoclonal antibody–drug conjugates 2005 ·Expert Opinion on Therapeutic Patents ·Philip R. Hamann	12
6	Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 2004 ·Cancer Immunology Immunotherapy ·John F. DiJoseph,Andrew G. Popplewell,Simon Tickle,Heather M. Ladyman,Alastair D. G. Lawson,Arthur Kunz,Kiran Khandke,Douglas Armellino,Erwin R. Boghaert,Philip R. Hamann,K Zinkewich-Péotti,Sue Stephens,Neil Weir,Nitin K. Damle	55
7	Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles 2004 ·Bioorganic & Medicinal Chemistry Letters ·Allan Wissner,Philip R. Hamann,Ramaswamy Nilakantan,Lee M. Greenberger,Fei Ye,(unknown),Frank Loganzo	18
8	Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193- N -Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts 2004 ·Clinical Cancer Research ·Erwin R. Boghaert,Latha Sridharan,Douglas Armellino,Kiran Khandke,John F. DiJoseph,Arthur Kunz,Maureen Dougher,Fan Jiang,(unknown),Philip R. Hamann,Philip Frost,Nitin K. Damle	51
9	Antibody-Targeted Chemotherapy with Immunoconjugates of Calicheamicin: Differential Anti-Tumor Activity of Conjugated Calicheamicin Targeted to B-Cell Lymphoma Via B-Cell Lineage Specific Molecules CD19, CD20 and CD22. 2004 ·Blood ·John F. DiJoseph,Douglas Armellino,Maureen Dougher,Arthur Kunz,Erwin R. Boghaert,Philip R. Hamann,K Zinkewich-Péotti,Nitin K. Damle	5
10	An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker 2001 ·Bioconjugate Chemistry ·Philip R. Hamann,Lois M. Hinman,Carl F. Beyer,(unknown),Janis Upeslacis,David Flowers,Irwin D. Bernstein	147
11	Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia 2001 ·Bioconjugate Chemistry ·Philip R. Hamann,Lois M. Hinman,Irwin Hollander,Carl F. Beyer,(unknown),Ryan E. Holcomb,William Hallett,(unknown),Janis Upeslacis,Dan Shochat,Andrew Mountain,David Flowers,Irwin D. Bernstein	431
12	Calicheamicin Derivatives Conjugated to Monoclonal Antibodies: Determination of Loading Values and Distributions by Infrared and UV Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry and Electrospray Ionization Mass Spectrometry 1997 ·Analytical Chemistry ·Marshall M. Siegel,Keiko Tabei,Arthur Kunz,Irwin Hollander,Philip R. Hamann,(unknown),Stefan Berkenkamp,Franz Hillenkamp	48
13	Determinants of the response of neuroblastoma cells to DNA damage: the roles of pre-treatment cell morphology and chemical nature of the damage. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Theresa L. Hartsell,Lois M. Hinman,Philip R. Hamann,Nina F. Schor	17
14	Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. 1993 ·PubMed ·Lois M. Hinman,Philip R. Hamann,Ryan M. Wallace,Ana T. Menendez,Frederick E. Durr,Janis Upeslacis	168
15	Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content 1991 ·Analytical Chemistry ·Marshall M. Siegel,Irwin Hollander,Philip R. Hamann,(unknown),Lois M. Hinman,Bryan John Smith,(unknown),(unknown),David J. King,et al	65
16	The Efficient Synthesis of Two Prostaglandin Intermediates 1989 ·Synthetic Communications ·Philip R. Hamann,Allan Wissner	4
17	Reactions of the trisulfide moiety in calicheamicin 1989 ·Tetrahedron Letters ·George A. Ellestad,Philip R. Hamann,Nada Zein,G. O. MORTON,Marshall M. Siegel,(unknown),Donald B. Borders,William J. McGahren	22
18	Studies culminating in the total synthesis of (dl)-morphine 1988 ·The Journal of Organic Chemistry ·(unknown),Philip R. Hamann,P. L. Fuchs	55
19	Synthesis of thromboxane A2 1985 ·Journal of the American Chemical Society ·Shripad S. Bhagwat,Philip R. Hamann,W. Clark Still	50
20	Conjugate addition of moderately soft anions to a vinyl sulfone 1983 ·The Journal of Organic Chemistry ·Philip R. Hamann,P. L. Fuchs	17

About Philip R. Hamann

Philip R. Hamann is a scholar working on Radiology, Nuclear Medicine and Imaging, Organic Chemistry and Oncology, having authored 28 papers that have together received 2.0k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (12 papers), Chemical Synthesis and Analysis (6 papers) and CAR-T cell therapy research (5 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (892 citations), Oncology (930 citations) and Hematology (210 citations). Philip R. Hamann has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Lois M. Hinman, Janis Upeslacis, Arthur Kunz, Carl F. Beyer, Irwin Hollander, Nitin K. Damle, John F. DiJoseph, Erwin R. Boghaert, Maureen Dougher and Irwin D. Bernstein. Their work appears in journals such as Nature, Journal of the American Chemical Society and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact